MENDICINO, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 65
EU - Europa 59
AS - Asia 46
SA - Sud America 5
OC - Oceania 2
Totale 177
Nazione #
US - Stati Uniti d'America 62
SG - Singapore 40
IT - Italia 36
GB - Regno Unito 8
DE - Germania 6
BR - Brasile 5
FI - Finlandia 4
PL - Polonia 4
IN - India 2
MX - Messico 2
NZ - Nuova Zelanda 2
CA - Canada 1
HK - Hong Kong 1
IR - Iran 1
JP - Giappone 1
SA - Arabia Saudita 1
SE - Svezia 1
Totale 177
Città #
Singapore 26
Chandler 8
Santa Clara 8
Ashburn 5
Chicago 5
London 5
Munich 5
Catanzaro 4
Milan 4
Boardman 3
Pistoia 3
Auckland 2
Chennai 2
Helsinki 2
Lawrence 2
Princeton 2
Rome 2
Rozzano 2
Turku 2
Warsaw 2
Acri 1
Baependi 1
Bowmanville 1
Brooklyn 1
Centro Municipality 1
Clarksburg 1
Denver 1
Des Moines 1
Hanover 1
Mexico City 1
Riyadh 1
Santo André 1
Seattle 1
São Gonçalo 1
São Paulo 1
Tokyo 1
Turin 1
Vitória de Santo Antão 1
Totale 112
Nome #
COVID-19: high-JAKing of the inflammatory “flight” by ruxolitinib to avoid the cytokine storm 70
Belantamab mafodotin in multiple myeloma 24
Elotuzumab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 23
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 21
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 18
Elotuzumab in multiple myeloma 16
Isatuximab in multiple myeloma 15
Totale 187
Categoria #
all - tutte 2.209
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.209


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202126 0 0 0 0 0 10 9 0 2 0 5 0
2021/202215 0 2 0 1 0 7 1 1 0 0 3 0
2022/202326 5 2 1 1 1 2 4 3 3 2 2 0
2023/202441 5 8 4 8 3 9 0 0 0 0 1 3
2024/202570 7 2 1 2 4 10 0 0 12 1 14 17
2025/20269 9 0 0 0 0 0 0 0 0 0 0 0
Totale 187